Top Wall Street Forecasters Revamp CVS Health Expectations Ahead Of Q2 Earnings

Benzinga
07-31

CVS Health Corporation (NYSE:CVS) will release earnings results for the second quarter before the opening bell on Thursday, July 31.

Analysts expect the Woonsocket, Rhode Island-based company to report quarterly earnings at $1.46 per share, down from $1.83 per share in the year-ago period. CVS Health is projected to report quarterly revenue of $94.59 billion, compared to $91.23 billion a year earlier, according to data from Benzinga Pro.

On July 23, CVS Health announced the opening of its new Workforce Innovation and Talent Center (WITC) in Columbus.

CVS Health shares gained 3.8% to close at $62.30 on Wednesday.

Benzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.

Let's have a look at how Benzinga's most-accurate analysts have rated the company in the recent period.

  • UBS analyst Kevin Caliendo maintained a Neutral rating and cut the price target from $71 to $67 on July 22, 2025. This analyst has an accuracy rate of 70%.
  • Jefferies analyst Brian Tanquilut maintained a Buy rating and raised the price target from $74 to $80 on June 30, 2025. This analyst has an accuracy rate of 64%.
  • Mizuho analyst Ann Hynes maintained an Outperform rating and increased the price target from $70 to $76 on April 9, 2025. This analyst has an accuracy rate of 85%.
  • Leerink Partners analyst Michael Cherny upgraded the stock from Market Perform to Outperform and raised the price target from $55 to $75 on Feb. 13, 2025. This analyst has an accuracy rate of 79%.

Considering buying CVS stock? Here’s what analysts think:

Read This Next:

  • Wall Street’s Most Accurate Analysts Give Their Take On 3 Energy Delivering High-Dividend Yields

Photo via Shutterstock

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10